Is Compounded Semaglutide Still Legal in 2026?

US pharmacy law splits compounding into two tracks. A 503A pharmacy makes a preparation for one named patient under a prescription written for that person. A 503B outsourcing facility makes larger batches that are not tied to a single patient. The April 30 proposal would remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list. It does not cover the 503A patient-specific pathway, which operates under a separate section of the law. ¹³

So the lane most telehealth patients actually use, a prescription written for you and filled for you, sits outside the scope of this proposal.

The legal hook for a lot of mass compounding was the drug shortage. When a medication is in shortage, the rules open up. The FDA has since declared those shortages resolved: tirzepatide in October 2024 (reaffirmed that December) and semaglutide in February 2025. ⁴ With the shortages closed, the agency says it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances. ¹

Read it on its own line, because this is the whole story:

The shortage justification ended, so the FDA is moving on the bulk-manufacturing route, not on the prescription written for one person.

A compounded medication is prepared by a state-licensed 503A pharmacy under a prescription written for one specific patient. It is a distinct preparation made for that person. It is not a generic copy of a branded product, and it is not the same as the brand-name drug. Anyone who blurs that line, in either direction, is telling you something about how carefully they work.

That distinction is not a marketing detail. It is the legal basis for why patient-specific compounding stays available even as the bulk route narrows. That pathway has its own limits: the FDA says a 503A pharmacy cannot regularly compound drugs that are essentially copies of a commercially available product. ⁴

A proposal does not change a prescription on its own. The FDA extended the comment window once, and it closed on July 30, 2026. ² Any change becomes binding only through a final FDA determination, and the patient-specific 503A pathway is not what this proposal narrows. The honest move is to stay informed, not to panic. Your physician and your pharmacy are the right people to tell you how any future rule would reach your specific treatment, because that is a clinical and regulatory call, not a blog call.

Here is the filter to apply. A provider you can trust will tell you, in plain terms, whether your medication comes from a 503A patient-specific pharmacy or a branded manufacturer, and will never call a compounded preparation a generic version of a brand or claim it is the same as the brand. They will also show you the full cost, the recurring monthly charge, and how to cancel anytime, before checkout and before your card is ever charged. Pricing examples are illustrative, not a quote of any one brand's prices. If a provider cannot answer those questions clearly, that is your answer. (This is the standard sipra was built around.)

The direction of travel is clear. Mass bulk compounding of these GLP-1s is being squeezed. Patient-specific compounding through a licensed 503A pharmacy is not the target of the April 30 proposal, and it remains a legal pathway in 2026 within the FDA's 503A conditions. ⁴ The comment period has closed, and the final decision is the FDA's next step. The thing under your control is choosing a provider who is transparent about which lane your medication comes from.

Ask your current or prospective provider one question: is my medication a 503A patient-specific compounded preparation or a branded product, and what happens to my treatment if the rules change. A provider who answers cleanly is the one to keep. That clarity is what sipra is built to give.